0000950170-23-041483.txt : 20230810 0000950170-23-041483.hdr.sgml : 20230810 20230810173044 ACCESSION NUMBER: 0000950170-23-041483 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230810 DATE AS OF CHANGE: 20230810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Comera Life Sciences Holdings, Inc. CENTRAL INDEX KEY: 0001907685 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 874706968 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41403 FILM NUMBER: 231160826 BUSINESS ADDRESS: STREET 1: 12 GILL STREET STREET 2: SUITE 4650 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (617)871-2101 MAIL ADDRESS: STREET 1: 12 GILL STREET STREET 2: SUITE 4650 CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 cmra-20230810.htm 8-K 8-K
0001907685false00019076852023-08-102023-08-100001907685us-gaap:WarrantMember2023-08-102023-08-100001907685us-gaap:CommonStockMember2023-08-102023-08-10

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2023

Comera Life Sciences Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware

1-41403

87-4706968

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

12 Gill Street

Suite 4650

Woburn, Massachusetts

01801

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 871-2101

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock

CMRA

The Nasdaq Stock Market LLC

Warrants

CMRAW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On August 10, 2023, Comera Life Sciences Holdings, Inc. (the “Company”) announced via press release its results for the second fiscal quarter ended June 30, 2023. A copy of the Company’s press release is hereby furnished to the U.S. Securities and Exchange Commission and incorporated herein by reference as Exhibit 99.1.

The information in the press release attached hereto as Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

 

99.1

Press release dated August 10, 2023

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 10, 2023

COMERA LIFE SCIENCES HOLDINGS, INC.

By:

/s/ Michael Campbell

Name:

Michael Campbell

Title:

Executive Vice President and Chief Financial Officer

 

 

 EX-99.1 2 cmra-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

img108929964_0.jpg 

Comera Life Sciences Reports Financial Results for

Second Quarter 2023 and Recent Business Highlights

 

– Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company –

–Received notice that Nasdaq granted Comera’s request for the continued listing of its common stock, subject to Comera’s satisfaction of certain conditions –

 

– Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders –

– Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology –

WOBURN, Mass., August 10, 2023 — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the second quarter ended June 30, 2023, and provided a business update.

“We made substantial progress across our business, strengthening our partnerships, platform and pipeline. Recent key accomplishments include advancing our ongoing collaboration with Regeneron, bolstering our intellectual property to further protect our SQore platform, and strengthening our cash position,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. “We remain focused on creating value for shareholders and executing on our mission to reduce healthcare costs and improve patient quality of life by leveraging our SQore platform to transform the delivery of biologics from intravenous to self-administered subcutaneous forms.”

Recent Business Highlights

•
Advanced to final stage of technical evaluation as part of an ongoing research collaboration with Regeneron, a leading U.S. biotechnology company. The partnership includes an option to negotiate a license after the technical evaluation is complete.
•
On August 8, 2023, received formal notice that Nasdaq granted Comera’s request for the continued listing of its common stock, subject to Comera’s satisfaction of certain conditions. These conditions include satisfaction of specified interim milestones and demonstrated compliance with all applicable criteria for continued listing on Nasdaq by no later than

 

 

 

November 14, 2023. Comera is taking definitive steps to comply with these conditions; however, there can be no assurance that it will be able to do so.
•
In August 2023, announced the execution of a definitive agreement to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share. At the initial closing on July 31, 2023, Comera sold and issued a total of 4,399,016 shares of its common stock and accompanying warrants to purchase up to 10,997,550 shares of common stock, resulting in gross proceeds of approximately $2.25 million to Comera. Comera expects to sell and issue an additional 3,561,851 shares of its common stock and accompanying warrants to purchase up to an additional 8,904,641 shares of common stock in a second closing, resulting in additional gross proceeds of approximately $1.82 million, conditioned upon receipt of stockholder approval under the applicable Nasdaq listing standards.
•
In August 2023, received a Notice of Intention to Grant a European patent by the European Patent Office, which would represent the first granted patent in Europe for Comera’s SQore platform technology.
•
In August 2023, announced the significant expansion of its SQore technology patent portfolio with the issuance of four new patents and two new notices of allowance. The six new patents, three issued in the United States and three covering Canada, Korea and India, expand the number of proprietary viscosity reducing excipients in Comera’s SQore platform and significantly broaden claims covered by previously issued patents.
•
In July 2023, announced collaboration with Quality Chemical Laboratories to manufacture one of Comera’s lead SQore excipients, as part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by the Company. Ownership of proprietary sourcing for lead SQore excipients allows for full control over supply chain, manufacturing within the United States, and greater flexibility to support product development needs.
•
In April 2023, announced the issuance of one new patent granted in South Korea and two Notices of Allowance in the United States and Japan covering expansion of claims, geographic coverage, and exclusive rights pertaining to certain excipients in its proprietary SQore platform.

Second Quarter 2023 Financial Results

Comera reported revenues of $315 thousand for the three months ended June 30, 2023, compared to $147 thousand for the same period in 2022, with the increase primarily related to the expansion of its ongoing research collaborations.

 

Cost of revenue totaled $56 thousand for the three months ended June 30, 2023, compared to $55 thousand for the same period in 2022. The costs are relatively consistent across periods despite higher revenues in the three months ended June 30, 2023, primarily related to an increase in research activities performed under customer contracts, which had more favorable margins compared with the prior period.

 

 

 

R&D expense totaled $236 thousand for the three months ended June 30, 2023, compared to $369 thousand for the same period in 2022. The overall decrease of approximately $133 thousand is primarily related to both a reduction in employee compensation expense and lower lab supply expenses in the three months ended June 30, 2023.

General and administrative expenses totaled $1.5 million for the three months ended June 30, 2023, compared to $3.7 million for the same period in 2022. The overall decrease of approximately $2.2 million is primarily related to expenses in connection with the Company’s transition to a public company in the three months ended June 30, 2022, and an overall reduction in general and administrative spending.

 

Comera reported a net loss of $1.5 million, or $0.08 loss per share for the three months ended June 30, 2023, compared to a net loss of $9.3 million, or $1.14 loss per share, for the same period in 2022. The decrease was primarily due to higher non-operating expense in the prior year, primarily related to the reverse recapitalization in 2022.

 

Comera had approximately $0.8 million in cash and accounts receivables, at June 30, 2023. Subsequent to the end of the second quarter, as mentioned above, the Company announced the execution of a definitive agreement for a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders, as described above.

About Comera Life Sciences

Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.

To learn more about the Comera Life Sciences mission, as well as the proprietary SQore™ platform, visit https://comeralifesciences.com/.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events (including statements related to the second closing of the private placement, our ability to regain and maintain compliance with Nasdaq listing standards and our SQore platform) that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: the Company’s ability to maintain the listing of its securities on the Nasdaq Capital Market; the price of the Company’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company plans to operate, variations in performance across competitors, changes in laws and regulations affecting the Company’s business and changes in the capital structure; the Company’s ability to execute on its business plans, forecasts, and other expectations and

 

 

identify and realize additional opportunities; the risk of economic downturns and the possibility of rapid change in the highly competitive industry in which the Company operates; the risk that the Company and its current and future collaborators are unable to successfully develop and commercialize the Company’s products or services, or experience significant delays in doing so; the risk that we will be unable to continue to attract and retain third-party collaborators, including collaboration partners and licensors; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that the Company is unable to secure or protect its intellectual property; the risk that the Company is unable to secure regulatory approval for its product candidates; the effect of any resurgence of the COVID-19 pandemic or other public health emergencies on the Company’s business; general economic conditions; and other risks and uncertainties described in Item 1A of Part I of the Company’s Annual Report on Form 10-K filed with the SEC on March 17, 2023 under “Risk Factors” and in other filings that have been made or will be made with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Comera assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Comera can give no assurance that it will achieve its expectations.

 

Contacts

Comera Investor

John Woolford
ICR Westwicke
John.Woolford@westwicke.com

 

Comera Press

Jon Yu
ICR Westwicke
ComeraPR@westwicke.com 

 

 

 

 

 

 

 

COMERA LIFE SCIENCES HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)

 

June 30,

 

 

December 31,

 

 

2023

 

 

2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

476,302

 

 

$

446,607

 

Restricted cash - current

 

 

—

 

 

 

1,505,625

 

Accounts receivable

 

 

250,000

 

 

 

34,320

 

Deferred issuance costs

 

 

25,013

 

 

 

90,047

 

Prepaid expenses and other current assets

 

 

1,072,719

 

 

 

986,499

 

Total current assets

 

 

1,824,034

 

 

 

3,063,098

 

Restricted cash - non-current

 

 

50,000

 

 

 

50,000

 

Property and equipment, net

 

 

209,732

 

 

 

257,186

 

Right-of-use asset

 

 

213,206

 

 

 

313,629

 

Security deposit

 

 

43,200

 

 

 

43,200

 

Total assets

 

$

2,340,172

 

 

$

3,727,113

 

Liabilities, Convertible Preferred Stock and Stockholders’ Deficit

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,150,774

 

 

$

1,458,267

 

Accrued expenses and other current liabilities

 

 

959,773

 

 

 

1,295,764

 

Insurance premium financing

 

 

584,809

 

 

 

455,562

 

Deposit liability

 

 

—

 

 

 

1,505,625

 

Deferred revenue

 

 

36,310

 

 

 

144,280

 

Lease liability - current

 

 

221,879

 

 

 

199,184

 

Total current liabilities

 

 

3,953,545

 

 

 

5,058,682

 

Derivative warrant liabilities

 

 

46,591

 

 

 

277,507

 

Lease liability - noncurrent

 

 

—

 

 

 

120,302

 

Total liabilities

 

 

4,000,136

 

 

 

5,456,491

 

Commitments and contingencies (Note 15)

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 1,000,000 shares authorized; 4,305 shares designated Series A convertible preferred stock; 4,305 shares issued and outstanding at June 30, 2023 and December 31, 2022

 

 

4,690,398

 

 

 

4,517,710

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

Common stock, $0.0001 par value; 150,000,000 shares authorized; 19,155,138 and 16,709,221 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively

 

 

1,915

 

 

 

1,671

 

Additional paid-in capital

 

 

32,444,578

 

 

 

28,655,164

 

Accumulated deficit

 

 

(38,796,855

)

 

 

(34,903,923

)

Total stockholders’ deficit

 

 

(6,350,362

)

 

 

(6,247,088

)

Total liabilities, convertible preferred stock and stockholders’ deficit

 

$

2,340,172

 

 

$

3,727,113

 

 

 

 

 

COMERA LIFE SCIENCES HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

 

 

Three Months Ended June 30,

 

 

Six months ended June 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue

 

$

315,055

 

 

$

146,726

 

 

$

707,970

 

 

$

242,060

 

Cost of revenue

 

 

56,040

 

 

 

54,543

 

 

 

172,559

 

 

 

99,067

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

235,696

 

 

 

368,553

 

 

 

579,401

 

 

 

855,770

 

General and administrative

 

 

1,503,553

 

 

 

3,696,517

 

 

 

3,936,700

 

 

 

5,712,762

 

Total operating expenses

 

 

1,739,249

 

 

 

4,065,070

 

 

 

4,516,101

 

 

 

6,568,532

 

Loss from operations

 

 

(1,480,234

)

 

 

(3,972,887

)

 

 

(3,980,690

)

 

 

(6,425,539

)

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of derivative warrant liabilities

 

 

72,591

 

 

 

1,454,440

 

 

 

99,353

 

 

 

1,454,440

 

Reverse recapitalization issuance costs in excess of gross proceeds

 

 

—

 

 

 

(6,566,821

)

 

 

—

 

 

 

(6,566,821

)

Interest expense

 

 

(3,977

)

 

 

—

 

 

 

(11,595

)

 

 

(77

)

Other expense, net

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(426,666

)

Total other income (expense), net

 

 

68,614

 

 

 

(5,112,381

)

 

 

87,758

 

 

 

(5,539,124

)

Net loss and comprehensive loss

 

 

(1,411,620

)

 

 

(9,085,268

)

 

 

(3,892,932

)

 

 

(11,964,663

)

Less: accretion of convertible preferred
  stock to redemption value

 

 

(85,872

)

 

 

(201,168

)

 

 

(172,688

)

 

 

(201,168

)

Net loss attributable to common stockholders

 

$

(1,497,492

)

 

$

(9,286,436

)

 

$

(4,065,620

)

 

$

(12,165,831

)

Net loss per share attributable to common stockholders — basic and diluted

 

$

(0.08

)

 

$

(1.14

)

 

$

(0.21

)

 

$

(2.75

)

Weighted-average number of common shares used in computing net loss per share attributable to common stockholders — basic and diluted

 

 

19,154,681

 

 

 

8,142,383

 

 

 

19,094,394

 

 

 

4,430,401

 

 

 GRAPHIC 3 img108929964_0.jpg GRAPHIC begin 644 img108929964_0.jpg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cmra-20230810_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 cmra-20230810_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Class of Stock [Domain] Class of Stock [Domain] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Class of Stock [Axis] Class of Stock [Axis] Entity Ex Transition Period Entity Ex Transition Period Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation State Country Code Document And Entity Information [Line Items] Document And Entity Information [Line Items] Local Phone Number Local Phone Number City Area Code City Area Code Warrant [Member] Warrant [Member] Common Stock [Member] Common Stock [Member] Pre-commencement Tender Offer Pre Commencement Tender Offer Cover [Abstract] Cover [Abstract] Document And Entity Information [Table] Document And Entity Information [Table] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Securities Act File Number Entity File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Security 12b Title Document Type Document Type EX-101.SCH 6 cmra-20230810.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 7 cmra-20230810_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 10, 2023
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001907685
Document Type 8-K
Document Period End Date Aug. 10, 2023
Entity Registrant Name Comera Life Sciences Holdings, Inc.
Entity Incorporation State Country Code DE
Entity File Number 1-41403
Entity Tax Identification Number 87-4706968
Entity Address, Address Line One 12 Gill Street
Entity Address, Address Line Two Suite 4650
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code (617)
Local Phone Number 871-2101
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock
Trading Symbol CMRA
Security Exchange Name NASDAQ
Warrant [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Warrants
Trading Symbol CMRAW
Security Exchange Name NASDAQ
XML 9 cmra-20230810_htm.xml IDEA: XBRL DOCUMENT 0001907685 2023-08-10 2023-08-10 0001907685 us-gaap:WarrantMember 2023-08-10 2023-08-10 0001907685 us-gaap:CommonStockMember 2023-08-10 2023-08-10 0001907685 false 8-K 2023-08-10 Comera Life Sciences Holdings, Inc. DE 1-41403 87-4706968 12 Gill Street Suite 4650 Woburn MA 01801 (617) 871-2101 false false false false Common Stock CMRA NASDAQ Warrants CMRAW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

$0 !X;"]W M;W)K8F]O:RYX;6Q02P$"% ,4 " #5BPI7)!Z;HJT #X 0 &@ M @ %-$@ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " #5BPI799!YDAD! #/ P $P @ $R$P 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" !\% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports cmra-20230810.htm cmra-20230810.xsd cmra-20230810_def.xml cmra-20230810_lab.xml cmra-20230810_pre.xml cmra-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cmra-20230810.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "cmra-20230810_def.xml" ] }, "inline": { "local": [ "cmra-20230810.htm" ] }, "labelLink": { "local": [ "cmra-20230810_lab.xml" ] }, "presentationLink": { "local": [ "cmra-20230810_pre.xml" ] }, "schema": { "local": [ "cmra-20230810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 2, "nsprefix": "cmra", "nsuri": "http://comeralifesciences.com/20230810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cmra-20230810.htm", "contextRef": "C_59edb35c-4774-4619-81e5-f70db77f9738", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cmra-20230810.htm", "contextRef": "C_59edb35c-4774-4619-81e5-f70db77f9738", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "cmra_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://comeralifesciences.com/20230810", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "cmra_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://comeralifesciences.com/20230810", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://comeralifesciences.com/20230810/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0000950170-23-041483-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-041483-xbrl.zip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end